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ABSTRACT 
 
OBJECTIVE: The objective of this study is to determine if Iron Sucrose (Venofer) is a safe 
treatment for people with Chronic Kidney Disease. 
 
STUDY DESIGN: This paper looks at three randomize controlled trials from 2001, 2007 and 
2008. 
 
DATA SOURCES: Randomized controlled trials that compared Iron Sucrose to Iron Dextran 
and Iron Gluconate were found using OVID, Cochrane, Medline and Pubmed. 
 
OUTCOME MEASURED: Adverse reactions that were analyzed based on serious and non-
serious reactions to the iron preparations.  Adverse reactions were also self reported or observed 
by the same person for a minimum of one hour following infusion of iron therapy.  Examples of 
serious adverse reactions included anaphylaxis and death where as non serious adverse reactions 
were reactions such as GI upset and headaches. 
 
CONCLUSIONS: After reviewing all three RCT, Iron Sucrose (Venofer) is a safe iron 
preparation for treating anemia associated with CKD. 
 
KEY WORDS: CKD, Iron Sucrose, Venofer, parenteral iron, allergy, iron replacement, anemia 
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Introduction 
The diagnosis of Chronic Kidney disease has nearly doubled over the last ten years. Due 
to the increase in end organ damage from high blood pressure and diabetes, to name a few, the 
number of people diagnosed with CKD will continue to rise over the years to come.   
 One of the major co morbidities that is strongly associated with CKD is anemia.  There 
are many causes of the anemia associated with CKD; however some causes still remain 
unknown.  A few of the major causes of anemia associated with CKD are as follows: a 
deficiency in EPO, frequent blood draws, GI hemorrhages, poor nutrition, coagulation of the 
dialyzer for those on dialysis, and anticoagulation leading to a lack of iron storage.  However, the 
deficiency in erythropoietin of those with kidney disease remains the most significant cause of 
anemia in those with renal insufficiency. Besides the deficiency in EPO, patients can already 
have a deficiency in iron stores due to their low protein diet and a reduction in GI absorption due 
to uremia. Therefore,  the replacement of primarily EPO without sufficient iron replacement 
therapy will not suffice in correcting the anemia in these patients. 
 Iron deficiency anemia is found in about 20-40% of patients on hemodialysis. The human 
body contains about 2-4 g of iron.  In a patient with chronic kidney disease, about 1-1.5 grams of 
iron is lost during one year of dialysis.  To correct this imbalance, it is necessary to use 
supplements of iron, other than those of the oral route due to the lack of efficacy. 
 CKD is of relevance to physician assistants because 26 million Americans are affected 
and millions of others are at an increased risk of developing renal insufficiency.  Because obesity 
is on the rise in America, co morbidities of obesity including hypertension and diabetes are also 
on the rise putting more people at risk for developing CKD.  CKD is associated with high rates 
of morbidity and mortality, placing the patient in need of a good health care system. 
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 CKD can be associated with a major source to health care costs. It is estimated that 35 
billion dollars is spent each year on patients with CKD.   Many of the expenses related to CKD 
are associated with hospital stays, dialysis costs, multiple medications and the treatments of 
CKD co morbidities.  In 2005, it was estimated that only 6.6 and 1.2% of Medicare patients were 
CKD and end stage renal failure patients, but used 19.4 and 8.2 % of all Medicare funds.  The 
NHANES study showed that the number of physician visits greatly increased between early 
stages of CKD with 4-5 visits and late stages of CKD and ESRD with 6-7 visits per year.  It was 
also estimated that patients with late stages of CKD had 2 hospitalizations per year with 14 visits 
to the hospital. 
 CKD is a slowly progressing condition which is characterized by a decrease in the 
function of the kidneys (decrease in the glomerular filtration rate) leading to volume overload, 
hypertension, organ damage and uremia. The most common causes of CKD are hypertension and 
uncontrolled diabetes.  CKD is treated by a number of variables, all of which are important in 
combination with each other in preventing the progression or slowing the progression of the 
disease state.  These methods include the use of ACE inhibitors for control of hypertension, but 
also as kidney protection, diuretics, diet restriction, glucose control, parenteral iron replacement, 
EPO, dialysis and transplant. 
 Parenteral iron replacement therapy is being recommended in the treatment of anemia 
associated with CKD because oral iron supplementation has not shown to be effective.  There are 
a variety of parenteral iron replacements, some of which include Iron Sucrose and Iron Dextran.   
Objective 
The goal of this review is to determine if iron sucrose (Venofer) is a safe treatment for 
people with chronic kidney disease. 
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Methods 
 The studies chosen were all forms of randomized controlled trials. The first study was a 
head to head, open label prospective RTC.  The second; a prospective open label study and the 
third a double blinded RTC.  The inclusion criteria included people with CKD who were anemic 
as a result of CKD, some also on hemodialysis.  The subjects studied had either overt iron 
deficiency anemia or were already being treated with a form of iron therapy to maintain Hgb 
levels and prevent iron deficiency anemia.  Iron sucrose (Venofer) was the intervention studied 
in which its safety was compared to two alternative forms of parenteral iron which included Iron 
Dextran and Iron Gluconate.  The outcomes measured were several adverse reactions, looking at 
the safety parameters of each type of iron therapy.  Common adverse reactions measured 
included: hypotension, pruritis, nausea, vomiting, fever, headache and urticaria.   
After using Cochrane Database, I searched OVID, Medline and Pub med to find qualified 
articles.  Qualified articles were based on relativity to the topic chosen and were all patient 
oriented evidence that matters or POEMs.  Each article used was in English and all data used was 
published between 2001 and 2008.  In order to locate the RTC’s needed, key words searched 
were ‘CKD’, ‘iron sucrose’, ‘Venofer’, ‘parenteral iron’, ‘allergy’, ‘iron replacement’ and 
‘anemia’.  Each article contained slightly different inclusion and exclusion criteria.  However, all 
subjects studied had CKD, some in different stages of kidney disease so that patients on 
hemodialysis were included.  Subjects excluded were those that did not have an anemia due to 
iron deficiency, previous hypersensitivity to iron replacement therapy or some form of allergy 
such as atopic allergy, asthma or eczema.  Patients using a form of therapy to prevent allergic 
reactions, such as anti-histamines, corticosteroids or immunosuppressive agents were also 
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excluded from the study.  Statistics included were P-values, Confidence Intervals, NNT, RRR, 
and ARR. 
Table 1. Demographics and Characteristics 
Study Type  # pt Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Tokgoz 
 2007 
  (1) 
Randomized, 
double 
blinded, 
controlled 
60 21-80 Patients with 
end stage renal 
failure 
The Hgb levels 
had to be 
below 10g/dl, 
transferrin sat 
below 20%, 
and serum 
ferritin level 
below 
100mcg/L 
0 75 mg of iron 
sucrose or Iron 
Dextran, 
diluted in 100 
ml saline 
administered 
over 30 
minutes.  
Bahner 
2001 
(2) 
Prospective, 
open 
randomized 
controlled 
trial 
59 44-74 Hemodialysis 
for 3 months, 
rHuEpo 
therapy for 
min 4 mo, 
hemoglobin 
btw 9 and 12, 
serum ferritin 
btw 100 and 
600 mcg/L, 
normal serum 
B12 and folic 
acid conc. 
No infection, 
malignancy or 
surgery;  
No chronic 
inflammatory 
disease and no 
blood 
transfusions in 
the last 3 
months. 
4 Iron sucrose 
was given to 
27 pt (250 mg 
diluted in 
100ml of NSS, 
infused over 60 
minutes once a 
month). 
Iron Gluconate  
was given to 
28 pt (62.5 mg 
over 5 min 
1X/week at 
dialysis) 
Anirban 
2008 
(3) 
Head to Head, 
open label, 
prospective 
randomized 
control trial 
370 27-57 Adult CKD 
patients who 
were on 
conservative 
management 
or on renal 
replacement 
therapy 
Iron overload, 
hypersensitive 
to iron 
preparations, 
NON- iron 
deficiency 
anemia, atopic 
allergy, eczema 
or asthma, liver 
problems, 
infections, 
inflammatory 
joint disease, 
steroids, a goal 
of >1L/h 
volume 
removal 
31 Iron dextran-
100mg in 
100ml NSS 
over 30min, 
Iron 
Gluconate-
125mg diluted 
in 100ml NSS 
over 60. Iron 
sucrose-100mg 
diluted in 
100ml of NSS 
over 15 min. 
 
Outcomes Measured 
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 The outcomes of each study were the occurrences of adverse drug reactions.  The adverse 
drug reactions measured had slightly different ways of being monitored.  Bahner et al measured 
adverse reactions based on observation of the patients during the trial period and then self 
reported adverse reactions by the patient. Patients also had the opportunity to fill out 
questionnaires about the adverse reactions they were having.  Anirban et al measured outcomes 
based on timing of drug administration such as adverse reactions at time of test dose, time of 
infusion and within the minutes after infusion and then again at 48 hours after. Sav et al 
measured outcomes by having each subject observed by the same person for an hour after 
infusion of iron therapy. 
Results 
 In the study completed by Anirban et al, the efficacy of parenteral iron replacement is not 
quantified.  However, Anirban et al states that the efficacy of all offered iron therapies are 
equivocal in nature, but the adverse event profile of each iron therapy is of concern. Sav et al 
also refrains from discussing efficacy of iron replacement.  In comparison, Kosch et al discusses 
efficacy of two iron supplements, Iron Dextran and iron sucrose.  The study concludes that from 
baseline to 6 months of time, the efficacy of both parenteral supplements is equivocal and that 
there is no statistically significant difference in the hemoglobin level, transferrin saturation and 
ferritin levels.  While there is not a significant difference in comparison between the two forms 
of iron replacement, both iron sucrose and Iron Dextran had an increase in ferritin and transferrin 
that was statistically significant with a p vale of less than 0.05.  This was proven based on 
comparison of baseline values and values after treatment at the 6 month mark.  Moreover, it 
appears that the decrease in hypochromic RBC is greater with the Iron Gluconate therapy, 
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however, this is not the case due to the factor that the baseline for the hypochromic RBC group’s 
baseline was much higher. 
Table 2. Percent Mean Change comparing Iron Sucrose to Iron Gluconate 
 Iron Sucrose  
(Baseline) 
Iron 
Sucrose  
(After tx) 
% 
mean 
change 
Iron 
Gluconate 
(Baseline) 
Iron 
Gluconate 
(After tx) 
% mean 
change 
Hemoglobin 11.34 11.43 0.8% 11.33 11.42 0.8% 
Ferritin 412 650* 58% 369 650* 76% 
Hypochromic 
RBC 
6.3 4.6 27% 10.8 5.2 52% 
Transferrin 
Sat 
21.9 33.3* 52% 25.7 34.4* 34% 
White Cell 
Count 
7.3 7.7 5% 7.3 7.2 Decrease 
1% 
Platelets  223.8 250.5 12% 227.6 230.3 1% 
*= p value < 0.05 
 
Sav et al compared the safety of Iron Sucrose and Iron Dextran.  The adverse reactions 
anticipated were: hypo or hypertension, chest pain, skin reactions, nausea, vomiting, flushing, 
myalgia, syncope, headache, fever, bronchospasm, paresthesias and dyspnea.  These were 
considered early reactions.  Late adverse reactions examined were considered as adverse 
reactions occurring within 48 hours of administration of the iron therapy.  The p value was 
greater than 0.05 meaning that there was no significant difference in the safety of either Iron 
Sucrose or Iron Dextran.  While no serious reactions occurred, the patients who were using Iron 
Sucrose reported diarrhea as the only adverse reaction while those on Iron Dextran reported 
having headaches.  Using Iron Dextran as the control, for every 17 subjects, one subject would 
have an adverse reaction calculated in table 3 as NNH. 
Ganglui et al compared serious and non-serious adverse reactions of Iron Sucrose, Iron 
Dextran and Iron Gluconate.  Ganglui et al listed a number of serious adverse reactions; however 
the common theme of all of the serious adverse reactions were those that need immediate 
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attention and or resuscitation.  Table 4 lists the serious adverse reactions.  Of all three iron 
therapies, Iron Dextran had the most serious side effects compared to the other two therapies. 
The OR was 4.908, with a 95% CI and a p value of 0.018.  The non serious adverse reactions 
were not statistically significant with a 95% CI.  Also, the number of people that discontinued 
their therapy with Iron Dextran was statistically significant with a p value of 0.009 and 95% CI.  
Those with serious adverse reactions had anaphylactic reactions, pruritis, and hypotension. 
However, it should be noted that those with the serious reactions had also had previous 
sensitivity to other iron preparations.  Fewer patients experienced serious adverse reactions such 
as pruritis and postural dizziness on Iron Gluconate, while non-serious reactions were mostly 
intestinal discomforts.  The only serious adverse reaction with Iron Sucrose was hypotension.  As 
with Iron Gluconate, the majority of non-serious adverse reactions were gastrointestinal related.  
Because there were three iron preparations compared in this randomized control trial, two NNH 
were calculated using Iron Dextran and Iron Gluconate as the control.  NNH calculated were 8 
and 4 respectfully. 
Kosch et al found that many of the adverse effects that occurred were also common 
symptoms of people diagnosed with chronic kidney disease.  The most common side effects 
were flu syndrome, infections, sinusitis and pneumonia in which the physician following the 
subjects ruled that these were not reactions due to the iron replacement therapy.  Although Kosch 
et al could not relate adverse reactions to the iron preparations, more subjects dropped out of the 
Iron Sucrose Group than the Iron Gluconate group.  For every six patients participating in the 
study, one person would have some sort of adverse event.   
 
Table 3. Numbers Needed to Harm comparing Iron Gluconate, Iron Sucrose and Iron Dextran 
Author RRI ARI NNH 
Kosch et al 0.37 0.17 6 
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(Iron Sucrose vs. 
Iron Gluconate) 
Sav et al 
(Iron Sucrose vs. 
Iron Dextran) 
0.16 0.06 17 
Ganguli et al 
(Iron Sucrose vs. 
Iron Dextran) 
-0.6 -0.12 8 
Ganguli et al 
(Iron Sucrose vs. 
Iron Gluconate) 
-0.47 -0.07 14 
RRI-relative risk increase, ARI-absolute risk increase, NNH-numbers needed to harm 
 
Table 4. Serious Adverse Reactions listed by Ganguli et al 
Death Bradycardia Sepsis 
Anaphylaxis Arrhythmias Cyanosis 
Cardiac Arrest Coma  
Myocardial Infarction Seizures  
Respiratory depression Hypotension  
Tachycardia hypertension  
 
Discussion 
 Anemia is a common problem for people with CKD.  However, it is known that oral 
preparations of iron therapy are not as effective in people with chronic kidney disease.  
Therefore, parenteral interventions of iron replacement therapy are necessary to correct anemia 
in these people.  Different forms of parenteral iron therapy have caused adverse reactions in the 
past leading to the need to find an effective yet safe iron replacement therapy for these patients.  
Over all, the articles that compared Iron Sucrose to Iron Dextran observed that Iron Sucrose has 
led to less adverse reactions and seems to be safer without using a test dose on patients.  It was 
also noted that subjects who had previous reactions to Iron Dextran had no reaction to Iron 
Sucrose.  
Iron Sucrose labeled use is for people with chronic kidney disease who are affected by 
anemia and those on dialysis with anemia.  Off labeled uses include those with anemia who are 
receiving chemotherapy.  The latest data also shows the Iron Sucrose should be used in anyone 
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who has had sensitivity to Iron Dextran. The majority of the articles share the limitation of small 
sample size.  Also, the open label study was a limitation to biases.  Limitations that I ran across 
were the inability to compare Iron Sucrose to a placebo or Iron Sucrose to each form of iron 
preparations individually. 
Conclusion 
In comparison to Iron Dextran and Iron Gluconate, Iron Sucrose is a safe treatment for 
anemia associated with Chronic Kidney Disease.  In the article by Kosch et al, it is concluded 
that although both Iron Sucrose and Iron Gluconate are effective and safe, there is a benefit to 
Iron Sucrose because it is a once monthly dose where as Iron Gluconate is a once weekly dose.  
Furthermore, Kosch et al note that this is an even greater benefit for those that are pre dialysis in 
that there are fewer visits needed to be made to a clinic.  Another benefit for those with CKD is 
that previous sensitivities to Iron Dextran were not present when using Iron Sucrose.  It was also 
observed that even those patients that had adverse reactions of some sort may not be definitively 
due to the iron preparation but based on numerous other health factors.  It seems that the rate at 
which the iron preparations are given can be a player in the number of adverse reactions that are 
had and for those that are hypersensitive may benefit from a slower infusion rate. 
Another area that is understudied is the effects of leukocytosis and its potential increased 
risk for associated morbidities and infection.  Although at this point, this reaction has only been 
seen with Iron Gluconate, it is worth further investigation.  As research in this area of medicine 
expands, it may be helpful to research randomized dosages of the iron preparations so that there 
aren’t as large of increases in hemoglobin, hematocrit and ferritin that is seen in some patients.   
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